Global PEGylated Proteins Market is valued at approximately USD 1.14 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 11.71% over the forecast period 2022-2029. PEGylation is a method of altering or binding biological molecules by coupling with polyethylene glycol. PEGylation helps in improving the stability and solubility of the drug, along with it reduces immunogenicity by altering the electrostatic binding, confirmation, and hydrophobicity of the molecule. The market growth is primarily driven by the factors such as rising consumption of protein-based drugs, increasing inclination towards protein treatments, coupled with the development of the biologics sector
The rising prevalence of chronic diseases such as cancer, autoimmune diseases, hepatitis, gastrointestinal disorders, etc. is stipulating the demand for PEGylated Proteins in the global market. According to National Cancer Institute, the number of cancer patients is expected to rise to 29.5 million cases, by the year 2040 from 18.1 million cases, in the year 2018. Accordingly, the high incidences of cancer are fostering the demand for PEGylated proteins in cancer therapy accelerating the growth of the market. In addition, the growing investment in the R&D of biologics, as well as the high presence of strong pipeline drugs are presenting various growth prospects to the market over the forecasting years. However, the high cost of the production process for PEGylation and patent expiration for novel PEGylated biologics are hampering the market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global PEGylated Proteins Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America dominated the market in terms of revenue, owing to the growing awareness regarding advanced therapeutics, increasing incentives to advance healthcare plans and the presence of key players. Whereas, the Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the presence of a huge population base, surging demand for proteins-based drugs, and the increased government funds in the regional market.
Major market players included in this report are:
- Thermo Fisher Scientific, Inc.
- Abcam plc.
- Enzon Pharmaceuticals, Inc.
- Merck KGaA
- Celares GmbH
- Profacgen
- Creative PEGworks
- NOF America Corp.
- Aurigene Pharmaceutical Services Ltd.
- Laysan Bio, Inc.
Recent Developments in the Market:
- In February 2022, Merck KGaA unveils the acquisition of Exelead- a full-service biopharmaceutical CDMO for USD 780 million with the objective of expanding the company's mRNA and lipid capabilities. Merck KGaA also declared that it has intend to invest more than USD 485.67 to augment the technologies.
Report Scope:Global PEGylated Proteins Market
- Historical Data: 2019-2020-2021
- Base Year for Estimation: 2021
- Forecast period: 2022-2029
- Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered: Protein Type, Product & Services, Application, End-User, Region
- Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
- Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Protein Type:
- Colony-stimulating factor
- Interferons
- Erythropoietin
- Recombinant factor VII
- Others
By Product & Services:
By Application:
- Cancer
- Autoimmune diseases
- Hepatitis
- Multiple sclerosis
- Hemophilia
- Gastrointestinal disorders
- Others
By End-User:
- Pharmaceutical & biotechnology companies
- Contract research organizations
- Academic & research institutes
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- RoLA
- Rest of the World
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Billion)
- 1.2.1. PEGylated Proteins Market, by Region, 2019-2029 (USD Billion)
- 1.2.2. PEGylated Proteins Market, by Protein Type, 2019-2029 (USD Billion)
- 1.2.3. PEGylated Proteins Market, by Product & Services, 2019-2029 (USD Billion)
- 1.2.4. PEGylated Proteins Market, by Application, 2019-2029 (USD Billion)
- 1.2.5. PEGylated Proteins Market, by End-User, 2019-2029 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global PEGylated Proteins Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Scope of the Study
- 2.2.2. Industry Evolution
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global PEGylated Proteins Market Dynamics
- 3.1. PEGylated Proteins Market Impact Analysis (2019-2029)
- 3.1.1. Market Drivers
- 3.1.1.1. Rising consumption of proteins-based drugs
- 3.1.1.2. Rising prevalence of chronic diseases
- 3.1.2. Market Challenges
- 3.1.2.1. High cost of the production process for PEGylation
- 3.1.2.2. Patent expiration for novel PEGylated biologics
- 3.1.3. Market Opportunities
- 3.1.3.1. Growing investment in the R&D of biologics
- 3.1.3.2. High presence of strong pipeline drugs
Chapter 4. Global PEGylated Proteins Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
- 4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. Industry Experts Prospective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Risk Assessment: COVID-19 Impact
- 5.1. Assessment of the overall impact of COVID-19 on the industry
- 5.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global PEGylated Proteins Market, by Protein Type
- 6.1. Market Snapshot
- 6.2. Global PEGylated Proteins Market by Protein Type, Performance - Potential Analysis
- 6.3. Global PEGylated Proteins Market Estimates & Forecasts by Protein Type 2019-2029 (USD Billion)
- 6.4. PEGylated Proteins Market, Sub Segment Analysis
- 6.4.1. Colony-stimulating factor
- 6.4.2. Interferons
- 6.4.3. Erythropoietin
- 6.4.4. Recombinant factor VII
- 6.4.5. Others
Chapter 7. Global PEGylated Proteins Market, by Product & Services
- 7.1. Market Snapshot
- 7.2. Global PEGylated Proteins Market by Product & Services, Performance - Potential Analysis
- 7.3. Global PEGylated Proteins Market Estimates & Forecasts by Product & Services 2019-2029 (USD Billion)
- 7.4. PEGylated Proteins Market, Sub Segment Analysis
- 7.4.1. Consumables
- 7.4.2. Services
Chapter 8. Global PEGylated Proteins Market, by Application
- 8.1. Market Snapshot
- 8.2. Global PEGylated Proteins Market by Application, Performance - Potential Analysis
- 8.3. Global PEGylated Proteins Market Estimates & Forecasts by Application 2019-2029 (USD Billion)
- 8.4. PEGylated Proteins Market, Sub Segment Analysis
- 8.4.1. Cancer
- 8.4.2. Autoimmune diseases
- 8.4.3. Hepatitis
- 8.4.4. Multiple sclerosis
- 8.4.5. Hemophilia
- 8.4.6. Gastrointestinal disorders
- 8.4.7. Others
Chapter 9. Global PEGylated Proteins Market, by End-User
- 9.1. Market Snapshot
- 9.2. Global PEGylated Proteins Market by End-User, Performance - Potential Analysis
- 9.3. Global PEGylated Proteins Market Estimates & Forecasts by End-User 2019-2029 (USD Billion)
- 9.4. PEGylated Proteins Market, Sub Segment Analysis
- 9.4.1. Pharmaceutical & biotechnology companies
- 9.4.2. Contract research organizations
- 9.4.3. Academic & research institutes
Chapter 10. Global PEGylated Proteins Market, Regional Analysis
- 10.1. PEGylated Proteins Market, Regional Market Snapshot
- 10.2. North America PEGylated Proteins Market
- 10.2.1. U.S. PEGylated Proteins Market
- 10.2.1.1. Protein Type breakdown estimates & forecasts, 2019-2029
- 10.2.1.2. Product & Services breakdown estimates & forecasts, 2019-2029
- 10.2.1.3. Application breakdown estimates & forecasts, 2019-2029
- 10.2.1.4. End-User breakdown estimates & forecasts, 2019-2029
- 10.2.2. Canada PEGylated Proteins Market
- 10.3. Europe PEGylated Proteins Market Snapshot
- 10.3.1. U.K. PEGylated Proteins Market
- 10.3.2. Germany PEGylated Proteins Market
- 10.3.3. France PEGylated Proteins Market
- 10.3.4. Spain PEGylated Proteins Market
- 10.3.5. Italy PEGylated Proteins Market
- 10.3.6. Rest of Europe PEGylated Proteins Market
- 10.4. Asia-Pacific PEGylated Proteins Market Snapshot
- 10.4.1. China PEGylated Proteins Market
- 10.4.2. India PEGylated Proteins Market
- 10.4.3. Japan PEGylated Proteins Market
- 10.4.4. Australia PEGylated Proteins Market
- 10.4.5. South Korea PEGylated Proteins Market
- 10.4.6. Rest of Asia Pacific PEGylated Proteins Market
- 10.5. Latin America PEGylated Proteins Market Snapshot
- 10.5.1. Brazil PEGylated Proteins Market
- 10.5.2. Mexico PEGylated Proteins Market
- 10.5.3. Rest of Latin America PEGylated Proteins Market
- 10.6. Rest of The World PEGylated Proteins Market
Chapter 11. Competitive Intelligence
- 11.1. Top Market Strategies
- 11.2. Company Profiles
- 11.2.1. Thermo Fisher Scientific, Inc.
- 11.2.1.1. Key Information
- 11.2.1.2. Overview
- 11.2.1.3. Financial (Subject to Data Availability)
- 11.2.1.4. Product Summary
- 11.2.1.5. Recent Developments
- 11.2.2. Abcam plc.
- 11.2.3. Enzon Pharmaceuticals, Inc.
- 11.2.4. Merck KGaA
- 11.2.5. Celares GmbH
- 11.2.6. Profacgen
- 11.2.7. Creative PEGworks
- 11.2.8. NOF America Corp.
- 11.2.9. Aurigene Pharmaceutical Services Ltd.
- 11.2.10. Laysan Bio, Inc.
Chapter 12. Research Process
- 12.1. Research Process
- 12.1.1. Data Mining
- 12.1.2. Analysis
- 12.1.3. Market Estimation
- 12.1.4. Validation
- 12.1.5. Publishing
- 12.2. Research Attributes
- 12.3. Research Assumption